

CI Global Health Sciences Corporate Class

SUMMARY OF INVESTMENT PORTFOLIO as at June 30, 2020

Category	% of Net Assets	Category	% of Net Assets	Top 25 Holdings	% of Net Assets
Country allocation		Sector allocation			
U.S.A.	65.3	Health Care	90.2	Bristol-Myers Squibb Co.	5.9
Japan	12.4	Financials	4.8	Alexion Pharmaceuticals Inc.	5.8
Germany	6.9	Consumer Staples	2.8	Takeda Pharmaceutical Co., Ltd.	5.6
France	3.0	Cash & Cash Equivalents	1.5	CVS Health Corp.	5.3
U.K.	2.7	Other Net Assets (Liabilities)	0.7	Merit Medical Systems Inc.	5.2
Switzerland	2.3	Fund(s)	0.0	Ionis Pharmaceuticals Inc.	5.1
Canada	1.6			SeaSpine Holdings Corp.	4.9
Cash & Cash Equivalents	1.5			Trupanion Inc.	4.8
Singapore	1.3			Biogen Inc.	4.8
Brazil	1.3			Fresenius Medical Care AG & Co., KGaA	4.5
Netherlands	1.0			Astellas Pharma Inc.	4.1
Other Net Assets (Liabilities)	0.7			Intercept Pharmaceuticals Inc.	3.7
Norway	0.0			Sanofi S.A.	3.0
				Sangamo Biosciences Inc.	2.8
				Sugi Holdings Co., Ltd.	2.8
				GlaxoSmithKline PLC	2.7
				CompuGroup Medical SE & Co., KGaA	2.4
				Novartis AG, Registered Shares	2.3
				CIGNA Corp.	2.0
				MacroGenics Inc.	1.7
				Aerie Pharmaceuticals Inc.	1.6
				Xenon Pharmaceuticals Inc.	1.6
				Fate Therapeutics Inc.	1.5
				Cash & Cash Equivalents	1.5
				Applied Genetic Technologies Corp.	1.4
				Total Net Asset (in \$000's):	\$182,843

The summary of investment portfolio may change due to ongoing portfolio transactions of the Fund and updates are available on a quarterly basis.

The prospectus and other information about the fund are available on the internet at www.ci.com.

